Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections

Basit Öğe Kaydı
dc.authorid0000-0002-8977-5931
dc.authorid0000-0002-1104-8232
dc.authorid0000-0002-0244-4006
dc.authorid0000-0002-7149-2968
dc.authorid0000-0003-0502-432X
dc.authorid0000-0003-1514-1685
dc.authorid0000-0002-4034-9202
dc.authorscopusid6505508467
dc.authorscopusid57211248494
dc.authorscopusid23060531400
dc.authorscopusid56029680900
dc.authorscopusid7004827493
dc.authorscopusid23494580100
dc.authorscopusid8726721500
dc.authorwosidKilic, Aysegul Ulu/AAM-1069-2021
dc.authorwosidOztoprak, Nefise/AAD-2679-2019
dc.authorwosidHatipoğlu, Çiğdem Ataman/AAA-4135-2021
dc.authorwosidbalkan, ilker inanc/AAI-1578-2019
dc.authorwosidÖrmen, Bahar/ABA-1027-2021
dc.authorwosidGüçLü, Ertuğrul/AAM-8247-2020
dc.authorwosidAkalin, Şerife/C-2591-2014
dc.contributor.authorBatırel, Ayşe
dc.contributor.authorBalkan, İlker İnanç
dc.contributor.authorKarabay, Oğuz
dc.contributor.authorAğalar, Canan
dc.contributor.authorAkalın, Şerife
dc.contributor.authorAlici, O.
dc.contributor.authorYılmaz, H.
dc.contributor.authorDogan, M.
dc.date.accessioned2022-05-11T14:37:22Z
dc.date.available2022-05-11T14:37:22Z
dc.date.issued2014
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları Ana Bilim Dalı
dc.description23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) -- APR 30, 2013 -- Berlin, GERMANY
dc.description.abstractThe purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A retrospective study was conducted in 27 tertiary-care centers from January 2009 to August 2012. The primary end-point was 14-day survival, and the secondary end-points were clinical and microbiological outcomes. Thirty-six and 214 patients [102 (47.7 %): colistin-carbapenem (CC), 69 (32.2 %): colistin-sulbactam (CS), and 43 (20.1 %: tigecycline): colistin with other agent (CO)] received colistin monotherapy and colistin-based combinations, respectively. Rates of complete response/cure and 14-day survival were relatively higher, and microbiological eradication was significantly higher in the combination group. Also, the in-hospital mortality rate was significantly lower in the combination group. No significant difference was found in the clinical (p = 0.97) and microbiological (p = 0.92) outcomes and 14-day survival rates (p = 0.79) between the three combination groups. Neither the timing of initial effective treatment nor the presence of any concomitant infection was significant between the three groups (p > 0.05) and also for 14-day survival (p > 0.05). Higher Pitt bacteremia score (PBS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Charlson comorbidity index (CCI), and prolonged hospital and intensive care unit (ICU) stay before XDR-ABSI were significant risk factors for 14-day mortality (p = 0.02, p = 0.0001, p = 0.0001, p = 0.02, and p = 0.01, respectively). In the multivariable analysis, PBS, age, and duration of ICU stay were independent risk factors for 14-day mortality (p < 0.0001, p < 0.0001, and p = 0.001, respectively). Colistin-based combination therapy resulted in significantly higher microbiological eradication rates, relatively higher cure and 14-day survival rates, and lower in-hospital mortality compared to colistin monotherapy. CC, CS, and CO combinations for XDR-ABSI did not reveal significant differences with respect to 14-day survival and clinical or microbiological outcome before and after propensity score matching (PSM). PBS, age, and length of ICU stay were independent risk factors for 14-day mortality.
dc.identifier.doi10.1007/s10096-014-2070-6
dc.identifier.endpage1322
dc.identifier.issn0934-9723
dc.identifier.issn1435-4373
dc.identifier.issue8en_US
dc.identifier.pmid24532009
dc.identifier.scopus2-s2.0-84903819291
dc.identifier.scopusqualityQ1
dc.identifier.startpage1311
dc.identifier.urihttps://doi.org/10.1007/s10096-014-2070-6
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8670
dc.identifier.volume33
dc.identifier.wosWOS:000338723600006
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorDoğan, Mustafa
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofEuropean Journal of Clinical Microbiology & Infectious Diseases
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAppropriate Antimicrobial Therapy
dc.subjectIn-Vitro
dc.subjectAntibiotic Combinations
dc.subjectPseudomonas-Aeruginosa
dc.subjectSerious Infections
dc.subjectApache-Ii
dc.subjectBacteremia
dc.subjectRifampicin
dc.subjectPneumonia
dc.subjectMortality
dc.titleComparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8670.pdf
Boyut:
344.8 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu